{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-044592","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2022-12-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.343179+00:00","generated_at":"2026-06-21T08:44:26.828406+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ADMA Biologics prelim Q4 revenue ~$48-50M (+85% YoY); launches public stock offering","bullets":["Preliminary Q4 2022 revenue $48-50M, up >85% YoY from $26.4M; full-year revenue $152-154M.","Launches underwritten public offering of common stock; 30-day option for additional 15% of shares.","Strategic review continues; received non-binding offers but board determined insufficient value.","Expects positive cash flow from operations by Q1 2024; may require additional capital.","Proceeds to accelerate commercialization, production, and plasma center buildout."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-044592","json":"https://secwatch.observer/filing/0001140361-22-044592.json","markdown":"https://secwatch.observer/filing/0001140361-22-044592.md","text":"https://secwatch.observer/filing/0001140361-22-044592.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/ny20006122x2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T08:44:26.828406+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"100bb4b81fa7320c0d169788d5875e9d27dc7886","claim":"ADMA BIOLOGICS, INC. reported year-ended December 31, 2022 results: revenue between $152 million and $154 million.","evidence_excerpt":"ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year-ended December 31, 2022"},{"label":"Revenue","value":"between $152 million and $154 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"},{"claim_id":"d89b56adec1288d68302097da82f7fbe05282810","claim":"ADMA BIOLOGICS, INC. reported quarter-ended December 31, 2022 results: revenue between $48 million and $50 million.","evidence_excerpt":"ADMA preliminarily estimates that its total revenue for the quarter- and year-ended December 31, 2022 will be between $48 million and $50 million and $152 million and $154 million, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036122044592/0001140361-22-044592-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter-ended December 31, 2022"},{"label":"Revenue","value":"between $48 million and $50 million"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}